Your browser is no longer supported. Please, upgrade your browser.
We’ve released a new Beta version of our Futures section! Try it now. We look forward to your feedback! ×
Settings
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E56.97 EPS (ttm)3.26 Insider Own0.80% Shs Outstand199.64M Perf Week1.54%
Market Cap37.08B Forward P/E25.45 EPS next Y7.30 Insider Trans-23.06% Shs Float195.68M Perf Month-1.78%
Income656.90M PEG2.30 EPS next Q1.32 Inst Own97.60% Short Float1.76% Perf Quarter2.92%
Sales2.23B P/S16.60 EPS this Y156.70% Inst Trans-0.07% Short Ratio2.75 Perf Half Y13.76%
Book/sh16.62 P/B11.17 EPS next Y23.95% ROA17.50% Target Price213.30 Perf Year23.97%
Cash/sh9.83 P/C18.90 EPS next 5Y24.73% ROE21.90% 52W Range147.78 - 203.30 Perf YTD0.37%
Dividend- P/FCF73.65 EPS past 5Y14.90% ROI19.50% 52W High-8.65% Beta0.65
Dividend %- Quick Ratio4.30 Sales past 5Y42.00% Gross Margin92.20% 52W Low25.67% ATR5.18
Employees2273 Current Ratio4.60 Sales Q/Q35.70% Oper. Margin41.00% RSI (14)58.06 Volatility2.27% 3.12%
OptionableYes Debt/Eq0.02 EPS Q/Q860.00% Profit Margin29.40% Rel Volume0.73 Prev Close181.34
ShortableYes LT Debt/Eq0.00 EarningsApr 23 BMO Payout0.00% Avg Volume1.25M Price185.71
Recom1.90 SMA203.70% SMA503.00% SMA2004.96% Volume911,621 Change2.41%
Jan-30-15Reiterated Stifel Buy $230 → $236
Jan-08-15Reiterated UBS Buy $220 → $213
Apr-25-14Reiterated Stifel Buy $219 → $220
Mar-11-14Reiterated UBS Buy $185 → $202
Mar-11-14Reiterated Stifel Buy $207 → $219
Mar-06-14Reiterated Barclays Overweight $181 → $193
Feb-10-14Reiterated Deutsche Bank Buy $125 → $205
Jan-31-14Reiterated Stifel Buy $138 → $207
Jan-31-14Reiterated Canaccord Genuity Buy $161 → $200
Jan-31-14Reiterated Barclays Overweight $141 → $181
Jan-30-14Reiterated Brean Capital Buy $142 → $200
Jan-10-14Reiterated Barclays Overweight $127 → $141
Jan-06-14Reiterated UBS Buy $130 → $150
Jan-06-14Reiterated Canaccord Genuity Buy $138 → $161
Oct-25-13Reiterated Stifel Buy $131 → $138
Oct-25-13Reiterated Barclays Overweight $121 → $127
Jul-26-13Reiterated Barclays Overweight $118 → $121
Apr-26-13Reiterated UBS Buy $120 → $123
Sep-24-12Reiterated Canaccord Genuity Buy $115 → $132
Apr-25-12Reiterated Canaccord Genuity Buy $95 → $100
Apr-16-15 09:30AM  The Zacks Analyst Blog Highlights: Medicines Co., Tekmira, GW Pharmaceuticals, Biogen and Alexion - Press Releases
06:10AM  Former Teva CEO's new gig at Ovid Therapeutics at CNBC
Apr-13-15 05:00PM  Alexion Up as Soliris Gains EU Nod for Label Updates - Analyst Blog
06:30AM  Alexion Announces Presentations at 2015 American Transplant Congress, Including Results from Studies Advancing the Understanding of Eculizumab (Soliris®) in Patients Undergoing Kidney Transplant Business Wire
Apr-10-15 02:00AM  Alexion Receives Approval for Important Updates to the European Label for Soliris® (eculizumab) Business Wire
Apr-09-15 01:00PM  Alexion Pharmaceuticals to Report First Quarter 2015 Results on Thursday, April 23, 2015 at noodls
12:28PM  Alexion Pharmaceuticals to Report First Quarter 2015 Results on Thursday, April 23, 2015 Business Wire
Apr-07-15 05:28PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
Apr-02-15 11:58AM  These 10 Pharma and Health Care Stocks Were the Worst S&P 500 Performers Last Quarter at TheStreet
Apr-01-15 04:18PM  Economic Indicators Move Equities and Bonds
Mar-31-15 06:15PM  3 Top-Rated Biotechs Could Take Buy Points Soon at Investor's Business Daily
Mar-30-15 10:25AM  Why Citigroup Removed Gilead Sciences From Its 'Most Preferred' List at Barrons.com
Mar-27-15 04:20PM  Stocks Finish Lower for the Week as Fed Talk Spooks Investors at TheStreet
01:11PM  These are the top-performing S&P 500 stocks of 2015 at MarketWatch
Mar-26-15 05:17PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
12:50PM  Cincinnati Childrens inks deal with Shire to develop drugs at bizjournals.com
12:12PM  Biotech Stock Selloff: Is It Justified? at Investor's Business Daily
09:47AM  The Biotech Selloff: It's Déjà Vu All Over Again at Barrons.com
08:22AM  One analyst is convinced the biotech stock plunge is 'misguided'
Mar-25-15 05:45PM  The Best Of The Best: Don't Miss These Top 9 Stocks at Investor's Business Daily
Mar-24-15 01:10PM  Two Healthcare Stocks Provide Antidotes To Wild Market Swings at Forbes
Mar-20-15 05:51PM  Learn The ABC's Of 3 Top-Ranked Biotech Stocks at Investor's Business Daily
04:32PM  Give Gilead Credit for Surge in Biotech Margins at Barrons.com
Mar-18-15 02:10PM  How the Weaker Euro Is Impacting Biotech Earnings at 24/7 Wall St.
Mar-17-15 10:52AM  Why These Could Be 2015's 10-Best Pharma Stocks at Investopedia
Mar-16-15 04:04PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material
Mar-13-15 02:44PM  Analyst Sees Upside To Outlook At 4 Biotechs
01:20PM  Affymetrix Hits 52-Week High on Stellar Q4, Positive Outlook - Analyst Blog
Mar-11-15 04:55PM  Analyst: Alexion Pharmaceuticals Pipeline Is Undervalued
Mar-09-15 08:00AM  Biotech pros top 8 stock picks at Fortune
Mar-07-15 05:16PM  New Data from First Natural History Study in Juveniles with Hypophosphatasia (HPP) Showing Substantial Disease Burden, Including Musculoskeletal Abnormalities and Growth Deficiencies, Presented in Late-Breaking Oral Session at ENDO 2015 at noodls
04:22PM  New Data from First Natural History Study in Juveniles with Hypophosphatasia (HPP) Showing Substantial Disease Burden, Including Musculoskeletal Abnormalities and Growth Deficiencies, Presented in Late-Breaking Oral Session at ENDO 2015 Business Wire
Mar-02-15 10:10PM  FDA Grants Priority Review for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia at noodls
06:30AM  FDA Grants Priority Review for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia Business Wire
Mar-01-15 02:19PM  Alexion Joins Patient Organizations Worldwide in Support of International Rare Disease Day 2015 at noodls
Feb-27-15 07:22AM  Alexion Receives CHMP Positive Opinions for Important Updates to the EU Label for Soliris® (eculizumab) Business Wire
06:30AM  Alexion Joins Patient Organizations Worldwide in Support of International Rare Disease Day 2015 Business Wire
Feb-23-15 10:00AM  Alexion to Present at Investor Conferences Business Wire
Feb-13-15 01:04PM  ALEXION PHARMACEUTICALS INC Financials EDGAR Online Financials
Feb-09-15 06:30AM  New Data from a Natural History Study in Patients with Infantile- and Juvenile-Onset Hypophosphatasia Accepted as Late-Breaking Abstracts at the ENDO 2015 Annual Meeting Business Wire
Feb-08-15 07:07PM  10-K for Alexion Pharmaceuticals, Inc. Company Spotlight
Feb-06-15 04:38PM  ALEXION PHARMACEUTICALS INC Files SEC form 10-K, Annual Report EDGAR Online
09:31AM  Canada Wants Alexion to Repay Sales Generated by 'Excessive Pricing' at The Wall Street Journal
02:01AM  Gilead, Amgen Q4 Earnings & Weak Outlook Affect Biotech ETFs - ETF News And Commentary Zacks
Feb-05-15 10:00AM  Alexion to Present at the 2015 Leerink Global Healthcare Conference Business Wire
Feb-03-15 02:15PM  Alexion Pharmaceuticals (ALXN) Earnings Report: Q4 2014 Conference Call Transcript at TheStreet
01:30PM  Biotechs Weigh On Nasdaq; McGraw Hill Rallies at Investor's Business Daily
06:47AM  PRESS DIGEST-Canada-Feb 3 Reuters
Jan-30-15 02:20PM  Qiagen (QGEN) Disappoints with Q4 Earnings, Revenue Miss - Analyst Blog Zacks
08:51AM  Alexion Pharmaceuticals (ALXN) Jumps: Stock Rises 5.8% - Tale of the Tape Zacks
Jan-29-15 06:49PM  Biogen, Alexion Earnings Top Views, Shares Jump Investor's Business Daily +5.78%
05:45PM  Alexion Pharmaceuticals Names COO to CEO at The Wall Street Journal
05:24PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or EDGAR Online
04:54PM  Thursday's Market Recap Yahoo Finance Contributors
04:35PM  Incyte's Phase III RESPONSE Data on Jakafi Published - Analyst Blog Zacks
04:24PM  Stocks Finish Strong; Facebook, Alexion Reverse Higher at Investor's Business Daily
04:20PM  Alexion Misses on Q4 Earnings, 2015 Outlook Disappoints - Analyst Blog Zacks
04:19PM  Salix Financial Results Need Correcting: Audit Committee - Analyst Blog Zacks
03:55PM  Baird Says Alexion Pharmaceuticals Guidance Is Conservative Benzinga
01:48PM  Alexion Pharmaceuticals: When Tax Rate Trumps FX at Barrons.com
01:28PM  Alexion Beats Q4 Estimates, Appoints New CEO at Investor's Business Daily
10:51AM  Celgene Q4 Earnings & Revenues In Line, Revlimid Sales Up - Analyst Blog Zacks
10:10AM  Vertex Posts Wider 4Q Loss, Affirms Kalydeco Outlook - Analyst Blog Zacks
09:49AM  Alexion Pharmaceuticals Inc Earnings Call scheduled for 10:00 am ET today CCBN
09:46AM  Zacks Rank #1 Additions for Thursday - Tale of the Tape Zacks
08:37AM  Pluristem Therapeutics (PSTI) in Focus: Stock Surges 20.4% - Tale of the Tape Zacks
08:00AM  Alexion (ALXN) Misses on Q4 Earnings, Appoints New CEO - Tale of the Tape Zacks
07:07AM  Q4 2014 Alexion Pharmaceuticals Inc Earnings Release - Before Market Open CCBN
06:51AM  Alexion beats Street 4Q forecasts AP
06:30AM  Alexion Appoints David L. Hallal as Chief Executive Officer, Effective April 1, 2015 Business Wire
06:25AM  Alexion Reports Fourth Quarter and Full Year 2014 Results and Provides Financial Guidance for 2015 Business Wire
Jan-28-15 10:00AM  Amgen Beats on Q4 Earnings & Revenues, Maintains Outlook - Analyst Blog Zacks
06:05AM  Up to Speed: Peltz receives ammo in fight against DuPont (Video) at American City Business Journals
Jan-27-15 06:55PM  Gilead Includes Pan-Genotypic Agent in HCV Licensing Deals - Analyst Blog Zacks
06:30PM  The Medicines Co. Gets CHMP Recommendation for 3 Drugs - Analyst Blog Zacks
03:20PM  Will Alexion's (ALXN) Soliris Drive Q4 Earnings Beat? - Analyst Blog Zacks
Jan-26-15 08:02AM  Apple, Facebook Lead This Week's IBD 50 Earnings at Investor's Business Daily
Jan-24-15 08:02AM  Apple, Facebook Lead Top IBD 50 Earnings This Week at Investor's Business Daily
Jan-23-15 05:20PM  Minerva Neurosciences Gains on Positive Data on MIN-202 - Analyst Blog Zacks
04:00PM  Sanofi's Cerdelga Cleared in the EU for Gaucher Disease - Analyst Blog Zacks
Jan-22-15 06:00PM  BioMarin to Raise Funds to Finance Prosensa Acquisition - Analyst Blog Zacks
05:50PM  Illumina Launches MiSeq FGx for Forensic DNA Analysis - Analyst Blog Zacks
05:10PM  Endo Prices $1.2B Senior Notes Offering for Auxilium Deal - Analyst Blog Zacks
04:10PM  Keryx to Raise $110 Million Through Issuance of Shares - Analyst Blog Zacks
04:00PM  Arena Pharmaceuticals to Raise Fund Via Share Issuance - Analyst Blog Zacks
03:20PM  Merrimack Reveals Additional Data from Oncology Candidate - Analyst Blog Zacks
03:10PM  Celgene to Use Zymeworks' Azymetric Platform for New Drugs - Analyst Blog Zacks
08:56AM  Kite Pharma (KITE) in Focus: Stock Tumbles 9.2% - Tale of the Tape Zacks
08:31AM  Keryx Biopharmaceuticals (KERX) in Focus: Stock Falls by 6.8% - Tale of the Tape Zacks
Jan-21-15 05:00PM  Alnylam to Raise $450 Million Through Issuance of Shares - Analyst Blog Zacks
12:50PM  Affymetrix Hits 52-Week High on Strong Top-Line Growth - Analyst Blog Zacks
10:00AM  Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2014 Results on Thursday, January 29, 2015 Business Wire
09:18AM  Applied Genetic Technologies (AGTC) in Focus: Stock Rises 6.6% - Tale of the Tape Zacks
08:44AM  AMAG Pharmaceuticals (AMAG) in Focus: Stock Rises 5.8% - Tale of the Tape Zacks
Jan-20-15 05:00PM  Supernus Downgraded as Lead Drugs Face Patent Challenges - Analyst Blog Zacks
04:15PM  Researchers to Present New Data on Asfotase Alfa in Children with Hypophosphatasia (HPP) as well as Burden of Disease Data in Adults with HPP at ENDO 2015 Annual Meeting Business Wire
Jan-19-15 04:30PM  Celgene Up as Otezla Gains EU Approval for Two Indications - Analyst Blog Zacks
09:32AM  Alkermes plc (ALKS) in Focus: Stock Moves 6.6% Higher - Tale of the Tape Zacks
08:44AM  BioDelivery Sciences International (BDSI) in Focus: Stock Up 5% - Tale of the Tape Zacks
Jan-16-15 04:16PM  Stocks End Five-Day Slide; HDFC Bank Rises at Investor's Business Daily
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH and aHUS registry; Phase III clinical trials for the treatment of delayed kidney transplant graft function and myasthenia gravis; and Phase II clinical trials for the treatment of antibody mediated rejection in presensitized kidney transplant patients and neuromyelitis optica. In addition, it develops Asfotase alfa, a targeted enzyme replacement therapy that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1007, a novel humanized antibody in Phase II clinical trials for the treatment of anti-phospholipid syndrome and graft versus host disease; and cPMP (ALXN 1101) that is in Phase II trial for treating metabolic disorders. The company primarily serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BELL LEONARDCEOMar 19Sale188.0715,9523,000,093949,426Mar 20 05:02 PM
MACKAY MARTINEVP & Global Head of R&DMar 02Sale180.3437066,72636,949Mar 03 09:13 PM
Sinha VikasEVP & CFOMar 02Sale180.3448787,826167,321Mar 03 09:13 PM
O'Neill JulieEVP. Global OperationsMar 02Sale180.346,5651,183,93222,090Mar 03 09:13 PM
Islam SaqibEVP, Chief Strat & Port. Off.Mar 02Sale180.3422841,11839,432Mar 03 09:12 PM
Moriarty John BEVP & General CounselMar 02Sale180.3428050,49533,342Mar 03 09:13 PM
BELL LEONARDCEOMar 02Sale180.341,230221,818965,378Mar 03 09:11 PM
Hallal DavidChief Operating OfficerMar 02Sale180.34730131,648132,858Mar 03 09:11 PM
Carmichael ClareEVP, Chief HR OfficerMar 02Sale180.34706127,32027,809Mar 03 09:12 PM
MACKAY MARTINEVP & Global Head of R&DFeb 10Sale173.973,897677,95632,219Feb 12 09:07 PM
Monnet DominiqueSVP, Chief Marketing OfficerFeb 10Sale171.1532555,6245,213Feb 12 09:07 PM
O'Neill JulieEVP. Global OperationsFeb 10Sale171.15795136,06423,555Feb 12 09:07 PM
Sinha VikasEVP & CFOFeb 10Sale171.151,985339,733162,708Feb 12 09:08 PM
BELL LEONARDCEOFeb 10Sale171.155,740982,401944,308Feb 12 09:06 PM
Hallal DavidChief Operating OfficerFeb 10Sale171.151,980338,877124,033Feb 12 09:06 PM
Carmichael ClareEVP, Chief HR OfficerFeb 10Sale171.151,490255,01421,670Feb 12 09:06 PM
Islam SaqibEVP, Chief Strat & Port. Off.Feb 10Sale171.151,500256,72534,560Feb 12 09:06 PM
Moriarty John BEVP & General CounselFeb 10Sale171.151,490255,01426,777Feb 12 09:07 PM
Sinha VikasEVP & CFOFeb 09Sale174.182,703470,810164,693Feb 09 08:48 PM
Moriarty John BEVP & General CounselFeb 09Sale174.161,455253,40328,267Feb 09 08:48 PM
BELL LEONARDCEOFeb 09Sale173.988,6601,506,667950,048Feb 09 08:46 PM
Hallal DavidChief Operating OfficerFeb 09Sale173.932,920507,876126,013Feb 09 08:46 PM
Carmichael ClareEVP, Chief HR OfficerFeb 09Sale173.751,665289,29423,160Feb 09 08:47 PM
Hallal DavidChief Operating OfficerFeb 04Sale174.38608106,023117,243Feb 05 08:10 PM
BELL LEONARDCEOFeb 04Sale174.352,223387,583924,718Feb 05 08:10 PM
Carmichael ClareEVP, Chief HR OfficerFeb 04Sale174.3520736,09016,065Feb 05 08:09 PM
Sinha VikasEVP & CFOFeb 04Sale174.37676117,874155,706Feb 05 08:10 PM
Sinha VikasEVP & CFOFeb 03Sale174.06895155,784156,382Feb 05 08:10 PM
BELL LEONARDCEOFeb 03Sale174.253,000522,750926,941Feb 05 08:10 PM
Hallal DavidChief Operating OfficerFeb 03Sale174.02765133,125117,851Feb 05 08:10 PM
Hallal DavidChief Operating OfficerDec 18Sale182.035,4941,000,073113,122Dec 19 04:49 PM
BELL LEONARDCEODec 18Sale182.0313,7352,500,182929,941Dec 19 04:49 PM
BELL LEONARDCEODec 17Option Exercise22.9016,680381,972960,356Dec 19 04:49 PM
BELL LEONARDCEODec 17Sale177.8416,6802,966,315943,676Dec 19 04:49 PM
Brennan David RDirectorDec 15Buy186.9950093,4951,268Dec 16 05:18 PM
Moriarty John BEVP & General CounselDec 11Sale195.533,570698,04220,962Dec 15 06:50 PM
Veneman Ann MDirectorDec 11Sale193.031,235238,3923,447Dec 15 06:50 PM
BELL LEONARDCEODec 09Option Exercise22.9016,665381,629960,341Dec 09 07:37 PM
BELL LEONARDCEODec 09Sale199.9416,6653,332,000943,676Dec 09 07:37 PM
BELL LEONARDCEODec 08Option Exercise21.8159,9341,307,1561,003,610Dec 09 07:37 PM
BELL LEONARDCEODec 08Sale198.8859,93411,919,423943,676Dec 09 07:37 PM
BELL LEONARDCEODec 05Option Exercise17.9856,7211,019,8441,000,397Dec 09 07:37 PM
BELL LEONARDCEODec 05Sale197.1256,72111,181,101943,676Dec 09 07:37 PM
Carmichael ClareSVP, Chief HR OfficerDec 04Option Exercise57.0210,000570,20026,272Dec 08 04:59 PM
Carmichael ClareSVP, Chief HR OfficerDec 04Sale196.2510,0001,962,50016,272Dec 08 04:59 PM
KELLER WILLIAM RDirectorDec 04Sale196.255,000981,2507,276Dec 08 04:59 PM
Sinha VikasEVP & CFODec 03Option Exercise19.1550,000957,400212,770Dec 04 05:20 PM
Sinha VikasEVP & CFODec 03Sale198.3650,0009,918,230162,770Dec 04 05:20 PM
Sinha VikasEVP & CFODec 02Option Exercise17.9825,000449,500187,770Dec 04 05:20 PM
Sinha VikasEVP & CFODec 02Sale200.1625,0005,004,000162,770Dec 04 05:20 PM
BELL LEONARDCEONov 20Sale191.965,2101,000,112943,676Nov 24 05:28 PM
Sinha VikasEVP & CFONov 06Option Exercise17.985,693102,360168,463Nov 10 05:44 PM
Sinha VikasEVP & CFONov 06Sale195.005,6931,110,135162,770Nov 10 05:44 PM
Sinha VikasEVP & CFONov 03Option Exercise17.9630,000538,800192,770Nov 04 06:35 PM
MACKAY MARTINEVP & Global Head of R&DNov 03Option Exercise104.869,375983,06333,801Nov 04 06:36 PM
Islam SaqibSVP, Chief Strat & Port. Off.Nov 03Option Exercise89.2328,1252,509,59455,425Nov 04 06:36 PM
Hallal DavidChief Operating OfficerNov 03Option Exercise20.3930,000611,736148,616Nov 04 06:36 PM
Islam SaqibSVP, Chief Strat & Port. Off.Nov 03Sale190.5028,1255,357,83127,300Nov 04 06:36 PM
Hallal DavidChief Operating OfficerNov 03Sale190.0130,0005,700,287118,616Nov 04 06:36 PM
Sinha VikasEVP & CFONov 03Sale190.9930,0005,729,619162,770Nov 04 06:35 PM
MACKAY MARTINEVP & Global Head of R&DNov 03Sale191.529,3751,795,50024,426Nov 04 06:36 PM
Sinha VikasEVP & CFOOct 31Option Exercise17.9319,307346,186182,077Nov 04 06:35 PM
Sinha VikasEVP & CFOOct 31Sale195.1819,3073,768,340162,770Nov 04 06:35 PM
Moriarty John BSVP & General CounselOct 27Option Exercise92.6510,000926,50034,532Oct 28 05:41 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerOct 27Option Exercise62.735,550348,140112,418Oct 28 05:41 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerOct 27Sale188.585,9101,114,532106,508Oct 28 05:41 PM
Moriarty John BSVP & General CounselOct 27Sale189.4910,0001,894,93724,532Oct 28 05:41 PM
BURNS M MICHELEDirectorOct 17Buy167.32101,673788Dec 08 04:59 PM
Moriarty John BSVP & General CounselOct 06Option Exercise95.6510,000956,50034,532Oct 08 04:55 PM
Moriarty John BSVP & General CounselOct 06Sale179.0010,0001,790,00024,532Oct 08 04:55 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerOct 03Option Exercise42.6610,025427,667116,893Oct 07 08:13 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerOct 03Sale172.4110,0251,728,374106,868Oct 07 08:13 PM
BELL LEONARDCEOSep 26Sale165.1260,0009,906,901948,886Sep 26 05:52 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerSep 24Sale159.507612,122106,868Sep 26 05:53 PM
BELL LEONARDCEOSep 18Sale161.4512,3882,000,0431,008,886Sep 18 05:33 PM
BELL LEONARDCEOSep 16Option Exercise17.6532,047565,6301,053,321Sep 18 05:33 PM
BELL LEONARDCEOSep 16Sale160.2632,0475,136,0051,021,274Sep 18 05:33 PM
BELL LEONARDCEOSep 10Sale165.3812,1992,017,4711,021,274Sep 12 08:59 PM
Carmichael ClareSVP, Chief HR OfficerSep 02Sale169.4630451,51616,272Sep 04 04:34 PM
BELL LEONARDCEOAug 15Option Exercise17.6535,000617,7501,062,186Aug 18 05:46 PM
BELL LEONARDCEOAug 15Sale170.0635,0005,952,1001,027,186Aug 18 05:46 PM
BELL LEONARDCEOAug 14Option Exercise17.6535,000617,7501,062,186Aug 18 05:46 PM
BELL LEONARDCEOAug 14Sale165.9235,0005,807,3661,027,186Aug 18 05:46 PM
BELL LEONARDCEOAug 13Option Exercise17.6524,542433,1661,051,728Aug 13 07:10 PM
BELL LEONARDCEOAug 13Sale162.5224,5423,988,5941,027,186Aug 13 07:10 PM
BELL LEONARDCEOAug 12Option Exercise17.6580,4581,420,0841,107,644Aug 13 07:10 PM
BELL LEONARDCEOAug 12Sale160.1680,45812,885,9101,027,186Aug 13 07:10 PM
BELL LEONARDCEOAug 04Sale157.885,145812,2931,027,186Aug 05 04:55 PM
Hallal DavidEVP, Chief Commercial OfficerAug 04Sale158.001,349213,142118,616Aug 05 04:55 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerAug 04Sale157.421,662261,632106,944Aug 05 04:55 PM
Carmichael ClareSVP, Chief HR OfficerAug 04Sale158.2318429,11416,576Aug 05 04:54 PM
Sinha VikasEVP & CFOAug 04Sale157.821,525240,676162,770Aug 05 04:54 PM
BELL LEONARDCEOJul 30Option Exercise17.6520,489361,6311,052,820Jul 30 05:08 PM
BELL LEONARDCEOJul 30Sale165.6920,4893,394,8331,032,331Jul 30 05:08 PM
BELL LEONARDCEOJul 29Option Exercise17.651,20021,1801,033,531Jul 30 05:08 PM
BELL LEONARDCEOJul 29Sale164.931,200197,9161,032,331Jul 30 05:08 PM
BELL LEONARDCEOJul 28Option Exercise17.65105,6001,863,8401,137,931Jul 30 05:08 PM
BELL LEONARDCEOJul 28Sale162.38105,60017,146,8011,032,331Jul 30 05:08 PM
BELL LEONARDCEOJun 20Option Exercise11.9290,2801,076,1381,122,611Jun 23 06:26 PM
BELL LEONARDCEOJun 20Sale163.6090,28014,770,1871,032,331Jun 23 06:26 PM